Last updated on July 2019

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)


Find a site near you

Start Over

Site JP81012

Nishinomiya, Japan
8.92miles
  Connect »